Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2014

01-07-2014 | Translational Research and Biomarkers

Regional Delivery of Oncolytic Vaccinia Virus: It’s Time for Clinical Trials

Authors: Stephanie Downs-Canner, David L. Bartlett, MD

Published in: Annals of Surgical Oncology | Issue 7/2014

Login to get access

Excerpt

Malignant peritoneal mesothelioma is both rare and deadly with very poor overall long-term survival. Historically, therapies have offered little survival benefit, but recent advances in surgical therapy—a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)—have shown promise and demonstrate a role for regional, intraperitoneal treatment.1 This regional delivery needs to be employed with other agents, including biologic therapies such as oncolytic viruses, to continue to improve survival for this disease. …
Literature
1.
Magee D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159–65.CrossRef
2.
Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–36.PubMedCrossRef
3.
Zhu ZB, Makhija SK, Lu B, et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol. 2006;1:701–11.PubMedCentralPubMedCrossRef
4.
Gauvrit A, Brandler S, Sapede-Peroz C, et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008;68:4882–92.PubMedCrossRef
5.
Belin LJ, Ady JW, Lewis C, et al. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma. Surgery. 2013;154:486–95.PubMedCrossRef
6.
McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751–7.PubMed
7.
Vasey PA, Shulman LN, Campos S, et al. Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene–Deleted Adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002;20:1562–9.PubMedCrossRef
8.
Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010;70:875–82.PubMedCentralPubMedCrossRef
9.
Kimball KJ, Preuss MA, Barnes MN, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res. 2010;16:5277–87.PubMedCentralPubMedCrossRef
10.
Kim KH, Dmitriev IP, Saddekni S, et al. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol. 2013;130:518–24.PubMedCrossRef
Metadata
Title
Regional Delivery of Oncolytic Vaccinia Virus: It’s Time for Clinical Trials
Authors
Stephanie Downs-Canner
David L. Bartlett, MD
Publication date
01-07-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 7/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3660-3

Other articles of this Issue 7/2014

Annals of Surgical Oncology 7/2014 Go to the issue

Healthcare Policy and Outcomes

Differences in Perioperative Care at Low- and High-Mortality Hospitals with Cancer Surgery

Pancreatic Tumors

Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies

Neuro-Oncology

Can There be a Place for Intraoperative Salvaged Blood in Spine Tumor Surgery?

Gastrointestinal Oncology

Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer

Hepatobiliary Tumors

HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma

Endocrine Tumors

Upregulation of HGF and c-MET is Associated with Subclinical Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma